Our study in ovarian cancer epithelial cells consistently showed that MECOM loss, as well as JIB-04 treatment, downregulated ZEB1 along with its non-canonical targets, N-cadherin and vimentin, suggesting potential transcriptional regulation of N-cadherin and vimentin. This evidence concerns the gene ZEB1 and ovarian cancer.